Cullinan Therapeutics, Inc. (CGEM)
21.86
-0.48
(-2.13%)
USD |
NASDAQ |
Sep 03, 15:18
Cullinan Therapeutics Cash from Investing (Quarterly) : 40.68M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 40.68M |
| March 31, 2026 | 32.41M |
| December 31, 2025 | 22.39M |
| September 30, 2025 | 67.39M |
| June 30, 2025 | 53.40M |
| March 31, 2025 | 36.80M |
| December 31, 2024 | 15.96M |
| September 30, 2024 | 19.88M |
| June 30, 2024 | -185.11M |
| March 31, 2024 | 12.96M |
| December 31, 2023 | 51.47M |
| September 30, 2023 | -42.96M |
| June 30, 2023 | 12.11M |
| March 31, 2023 | 15.18M |
| Date | Value |
|---|---|
| December 31, 2022 | -28.61M |
| September 30, 2022 | -57.98M |
| June 30, 2022 | 300.85M |
| March 31, 2022 | 35.86M |
| December 31, 2021 | -15.86M |
| September 30, 2021 | -25.59M |
| June 30, 2021 | -153.67M |
| March 31, 2021 | -137.73M |
| December 31, 2020 | 11.44M |
| September 30, 2020 | -1.941M |
| June 30, 2020 | 11.97M |
| March 31, 2020 | -26.89M |
| December 31, 2019 | -35.38M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Rallybio Corp. | 5.50M |
| MapLight Therapeutics, Inc. | 60.70M |
| Arrowhead Pharmaceuticals, Inc. | 43.68M |
| Oncolytics Biotech, Inc. | 0.00 |
| Sangamo Therapeutics, Inc. | -0.013M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -38.22M |
| Cash from Financing (Quarterly) | 1.10M |
| Free Cash Flow | -159.26M |
| Free Cash Flow Per Share (Quarterly) | -0.6167 |
| Free Cash Flow to Equity (Quarterly) | -37.91M |
| Free Cash Flow to Firm (Quarterly) | -38.22M |
| Free Cash Flow Yield | -12.08% |